Cancer Drugs Reimbursed with Limited Evidence on Overall Survival and Quality of Life: Do Follow-Up Studies Confirm Patient Benefits?

BACKGROUND AND OBJECTIVE: Cancer drug costs have increased considerably within healthcare systems, but many drugs lack quality-of-life (QoL) and overall survival (OS) data at the time of reimbursement approval. This study aimed to review the extent of subsequent literature documenting improvements i...

Descripción completa

Detalles Bibliográficos
Autores principales: Chauca Strand, Gabriella, Johansson, Naimi, Jakobsson, Niklas, Bonander, Carl, Svensson, Mikael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480259/
https://www.ncbi.nlm.nih.gov/pubmed/37505421
http://dx.doi.org/10.1007/s40261-023-01285-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480259/
https://www.ncbi.nlm.nih.gov/pubmed/37505421
http://dx.doi.org/10.1007/s40261-023-01285-4

Ejemplares similares